Given the shortage of these agents, nucleoside DNMT inhibitors are usually used at low doses to reprogramme and sensitize tumour cells to diverse radiotherapy, chemotherapy and immunotherapy regimens in clinical trials, some of which show good prospects.112. Here, DNMT1 is linked to neoplasm.